About Christian Qualls, PsyD

Dr. Qualls has had a multifaceted career in psychology, spanning a quarter-century of dedicated service to understanding the intricacies of the human mind and enhancing human potential across various domains. Throughout his career, the study of the interplay between cognition and behavior has been his pursuit. Dr. Qualls' training and practice of neuropsychology has focused on unraveling the mysteries of brain-behavior relationships to the benefit of the patient. In tandem with his clinical pursuits, Dr. Qualls recognized the transformative power of education in shaping future generations of psychologists. Embracing the role of educator with fervor, he has engaged in nurturing the minds of aspiring psychologists, imparting a profound appreciation for the complexities of human behavior. 

Dr.Qualls' passion for psychology transcended the confines of traditional academia and clinical practice. Recognizing the unique challenges faced by athletes, performers, and individuals striving for excellence in their respective fields, he additionally provided specialized consulting in sports and performance psychology. In the pursuit of optimizing mental performance, Dr. Qualls sought to enhance resilience, and unlock the full potential of his clients, whether on the field, stage, or in the boardroom. Throughout his career, Dr.Qualls has remained steadfast in dedication to advancing the frontiers of psychological science and fostering positive change in the lives of others.

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Mass General Psychiatry: Adult Outpatient Psychiatry Services
55 Fruit St.
Wang Ambulatory Care Center
Boston, MA 02114
Phone: 617-724-7792

Medical Education

  • Fellowship, The Guidance Center

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

1.Janssen Research & Development: Protocol 54861911ALZ2003 Investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer?s dementia. 2. Sunovion Pharmaceuticals Inc.: Protocol SEP360-321/SEP360- Evaluated the efficacy, safety, and tolerability of Dasotraline in adults with moderate to severe binge eating disorder. 3. Merck Sharp & Dohme 1Corp.: Protocol MK4305- Studied the safety and efficacy of Suvorexant (MK-4305) for the treatment of insomnia in subjects with Alzheimer?s disease. 4. vTv Therapeutics LLC: Protocol TTP488-301 Evaluated the efficacy and safety of TTP488 in patients with mild Alzheimer's disease receiving acetylcholinesterase inhibitors and/or Memantine. 5. Merck Sharp & Dohme Corp.,Protocol MK8931-019 Studied the efficacy and safety of MK-8931 (SCH 900931) in subjects with amnestic Mild Cognitive Impairment due to Alzheimer?s disease (Prodromal AD). 6. Merck Sharp & Dohme Corp., Protocol MK8931-017 phase 2/3;, efficacy and safety trial of MK-8931 with a long term double-blind extension in subjects with mild to moderate Alzheimer?s disease.

Publications

Reviews: Comments and Ratings